A new material developed at Cornell University could significantly improve the delivery and effectiveness of mRNA vaccines by ...

The US Department of Health and Human Services is terminating a contract with drugmaker Moderna to develop a vaccine to ...

Moderna, Inc. (NASDAQ:MRNA) announced today that its investigational H5 avian influenza vaccine, mRNA-1018, has shown ...

We spoke to Örn Almarsson about the therapeutic potential of mRNA lipid nanoparticles and the techniques being used to ...

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies. This ...

The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine ... Worldwide, flu leads to 3 to 5 million cases of severe illness and 290,000-650,000 respiratory ...

Action and drama are the name of the game at Amazon Prime Video in the final weekend of May. In a month were five of the Mission: Impossible movies topped the Prime Video charts, it’s refreshing ...

The Fund seeks to provide long-term capital appreciation. The Fund invests primarily in the common stocks of U.S. companies, emphasizing those companies with prospects for rapid earnings growth ...

Bath & Body Works reports a 3% increase in Q1 net sales and a 29% rise in earnings per share. Bath & Body Works, Inc. reported a 3% increase in net sales for the first quarter of 2025, reaching $1 ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

The Fund seeks to provide long-term capital appreciation. PRIMECAP Odyssey Growth Fund invests primarily in the common stocks of U.S. companies, emphasizing those companies with the potential for ...